

## DAFTAR PUSTAKA

- Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Sakai, K., Sugimachi, K., Tominaga, T., Uchino, J., Yoshida, M., Haybittle, J. L., Davies, C., Harvey, V. J., Holdaway, T. M., Kay, R. G., Mason, B. H., Forbes, J. F., ... Caffier, H. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. *Lancet*. [https://doi.org/10.1016/S0140-6736\(05\)66544-0](https://doi.org/10.1016/S0140-6736(05)66544-0)
- Abotaleb, M., Samuel, S. M., Varghese, E., Varghese, S., Kubatka, P., Liskova, A., & Büsselberg, D. (2019). Flavonoids in cancer and apoptosis. In *Cancers*. <https://doi.org/10.3390/cancers11010028>
- Abushouk, A. I., Abdo Salem, A. M., Saad, A., Afifi, A. M., Afify, A. Y., Afify, H., Salem, H. S. E., Ghanem, E., & Abdel-Daim, M. M. (2019). Mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy: Potential mechanisms, governing factors, and implications of the heart stem cell debate. In *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2019.00635>
- Agustin H, Massi MN, Djaharuddin I, Patellongi I, Susanto AD, Islam AA, Hatta M, Bukhari A, Tabri NA, Santoso A, Burhan E, Isbaniyah F, Farsida, Effendy Z. (2023). Correlation expression Toll-like receptor 4 with multidrugs resistant tuberculosis in diabetes mellitus condition. *Indian J Tuberc*. 70(1):59-64. doi: <https://doi.org/10.1016/j.ijtb.2022.03.012>.
- Amornsupak, K., Insawang, T., Thuwajit, P., O-Charoenrat, P., Eccles, S. A., & Thuwajit, C. (2014). Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. *BMC Cancer*. <https://doi.org/10.1186/1471-2407-14-955>
- Andersson, U., & Tracey, K. J. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. *Annual Review of Immunology*. <https://doi.org/10.1146/annurev-immunol-030409-101323>
- Ansó, E., Zuazo, A., Irigoyen, M., Urdaci, M. C., Rouzaut, A., & Martínez-Irujo, J. J. (2010). Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. *Biochemical Pharmacology*. <https://doi.org/10.1016/j.bcp.2010.02.004>
- Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., Mertens, A. C., Border, W., Durand, J. B., Robison, L. L., & Meacham, L. R. (2013). Modifiable risk factors and major cardiac events among

- adult survivors of childhood cancer. *Journal of Clinical Oncology*.  
<https://doi.org/10.1200/JCO.2013.49.3205>
- Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A., & Verrill, M. W. (2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. In *Annals of Oncology*.  
<https://doi.org/10.1093/annonc/mdn728>
- Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J. S., Cleland, J. G. F., & Pennell, D. J. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? *European Heart Journal*.  
<https://doi.org/10.1053/euhj.2000.2011>
- Bouma, J., Beijnen, J. H., Bult, A., & Underberg, W. J. (1986). Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. *Pharmaceutisch Weekblad. Scientific Edition*, 8(2), 109—133. <https://doi.org/10.1007/bf02086146>
- Cao, Y., Eble, J. M., Moon, E., Yuan, H., Weitzel, D. H., Landon, C. D., Nien, C. Y. C., Hanna, G., Rich, J. N., Provenzale, J. M., & Dewhirst, M. W. (2013). Tumor cells upregulate normoxic HIF-1a in response to doxorubicin. *Cancer Research*. <https://doi.org/10.1158/0008-5472.CAN-12-1345>
- Celio, L. A., DiGregorio, G. J., Ruch, E., Pace, J., & Piraino, A. J. (1983). Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. *European Journal of Clinical Pharmacology*.  
<https://doi.org/10.1007/BF00613829>
- Chen, Q., Wang, Z. Y., Chen, L. Y., & Hu, H. Y. (2017). Roles of High Mobility Group Box 1 in Cardiovascular Calcification. In *Cellular Physiology and Biochemistry*. <https://doi.org/10.1159/000477591>
- Chen, Z., Wang, C., Li, T. F., Li, K., Yue, Y., Liu, X., Xu, H. Z., Wen, Y., Zhang, Q., Han, M., Komatsu, N., Xu, Y. H., Zhao, L., & Chen, X. (2019). Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates. *Nanomedicine*.  
<https://doi.org/10.2217/nnm-2018-0330>
- Chou, D. K. H., Evans, J. E., & Jungalwala, F. B. (2001). Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain. *Journal of Neurochemistry*.  
<https://doi.org/10.1046/j.1471-4159.2001.00209.x>
- Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. In: Madame Curie Bioscience Database [Internet].

Austin (TX): Landes Bioscience; 2000-2013.

- Duyndam, M. C. A., van Berkel, M. P. A., Dorsman, J. C., Rockx, D. A. P., Pinedo, H. M., & Boven, E. (2007). Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. *Biochemical Pharmacology*. <https://doi.org/10.1016/j.bcp.2007.04.003>
- Egan, P. C., Costanza, M. E., Dodion, P., Egorin, M. J., & Bachur, N. R. (1985). Doxorubicin and cisplatin excretion into human milk. *Cancer Treatment Reports*.
- Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. In *Nature Reviews Cardiology*. <https://doi.org/10.1038/nrcardio.2015.65>
- Fachri M, Hatta M, Massi MN, Santoso A, Wikanningtyas TA, Dwiyantri R, Junita AR, Primaguna MR, Sabir M. 2021. The strong correlation between ADAM33 expression and airway inflammation in chronic obstructive pulmonary disease and candidate for biomarker and treatment of COPD. *Scientific Reports*.11. <https://doi.org/10.1038/s41598-021-02615-2>
- Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. *European Journal of Cancer*. <https://doi.org/10.1016/j.ejca.2012.12.027>
- Ferrari, S., Finelli, P., Rocchi, M., & Bianchi, M. E. (1996). The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. *Genomics*. <https://doi.org/10.1006/geno.1996.0369>
- Fu, A., Ma, S., Wei, N., Tan, B. X. X., Tan, E. Y., & Luo, K. Q. (2016). High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin. *Oncotarget*. <https://doi.org/10.18632/oncotarget.10360>
- Greene, R. F., Jenkins, J. F., Speyer, J. L., Myers, C. E., & Collins, J. M. (1983). Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. *Cancer Research*.
- Gunawan, I., Hatta, M., Benyamin, A. F., & Islam, A. A. (2020). The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer. *Asian Pacific Journal of Cancer Prevention : APJCP*, 21(3), 629–637. <https://doi.org/10.31557/APJCP.2020.21.3.629>

- Hatta M, Surachmanto EE, Islam AA, Wahid S. (2017). Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. *BMC Res Notes*. 10(1):202. doi: 10.1186/s13104-017-2517-9.
- Hasenfuss, G., & Mann, D. L. (2011). Pathophysiology of Heart Failure. In *Braunwald's Heart Disease 10th Edition*.
- Henson, K. E., McGale, P., Taylor, C., & Darby, S. C. (2013). Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *British Journal of Cancer*. <https://doi.org/10.1038/bjc.2012.575>
- Hoeger, C. W., Turissini, C., & Asnani, A. (2020). Doxorubicin Cardiotoxicity: Pathophysiology Updates. *Current Treatment Options in Cardiovascular Medicine*, 22(11), 52. <https://doi.org/10.1007/s11936-020-00842-w>
- Hong, R. A., Iimura, T., Sumida, K. N., & Eager, R. M. (2010). Cardio-oncology/onco-cardiology. In *Clinical Cardiology*. <https://doi.org/10.1002/clc.20823>
- Idrus, H. H., Hatta, M., Kasim, V. N., Achmad, A. F., Arsal, A. S. F., Hadju, V., & As'ad, S. (2019). Molecular impact on high motility group box-1 (HMGB-1) in pamps and damp. *Indian Journal of Public Health Research and Development*. <https://doi.org/10.5958/0976-5506.2019.02045.X>
- Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B., Lima E Silva, R., Seidel, C., Yang, M., Connelly, S., Shen, J., Han, B., Wu, M., Semenza, G. L., Hanes, J., & Campochiaro, P. A. (2013). Sustained delivery of a HIF-1 antagonist for ocular neovascularization. *Journal of Controlled Release*. <https://doi.org/10.1016/j.jconrel.2013.10.008>
- Iyer, N. V., Leung, S. W., & Semenza, G. L. (1998). The human hypoxia-inducible factor 1 $\alpha$  gene: HIF1A structure and evolutionary conservation. *Genomics*. <https://doi.org/10.1006/geno.1998.5416>
- Jiang, L., Ping, L., Yan, H., Yang, X., He, Q., Xu, Z., & Luo, P. (2020). Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. *Expert Opinion on Drug Metabolism & Toxicology*, 16(9), 823–835. <https://doi.org/10.1080/17425255.2020.1787986>
- Kang, R., Livesey, K. M., Zeh, H. J., Lotze, M. T., & Tang, D. (2011). HMGB1 as an autophagy sensor in oxidative stress. In *Autophagy*. <https://doi.org/10.4161/auto.7.8.15704>
- Karnina R, Arif SK, Hatta M, Bukhari A. Molecular mechanisms of lidocaine. *Ann Med Surg (Lond)*. 2021 Aug 17;69:102733. doi:

10.1016/j.amsu.2021.102733. PMID: 34457261; PMCID: PMC8379473.

- Karp, G. I., von Oeyen, P., Valone, F., Khetarpal, V. K., Israel, M., Mayer, R. J., Frigoletto, F. D., & Garnick, M. B. (1983). Doxorubicin in pregnancy: Possible transplacental passage. *Cancer Treatment Reports*.
- Kelly, S. J., Halasz, K., Smalling, R., & Sutariya, V. (2019). Nanodelivery of doxorubicin for age-related macular degeneration. *Drug Development and Industrial Pharmacy*.  
<https://doi.org/10.1080/03639045.2019.1569024>
- Kerget B, Afşin DE, Aksakal A, Aşkin S, Araz Ö. Could HIF-1 $\alpha$  be a novel biomarker for the clinical course and treatment of pulmonary embolism? *Turk J Med Sci*. 2020 Jun 23;50(4):963-968. doi: 10.3906/sag-1908-93. PMID: 32421278; PMCID: PMC7379473.
- Khattak MA, Abed A, Reid AL, McEvoy AC, Millward M, Ziman M, Gray ES. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.01041>
- Kim YA, Cho H, Lee N, Jung SY, Sim SH, Park IH, Lee S, Lee ES, Kim HJ. (2018). Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database. *Cancer Med*. 7(12):6084-6092. doi: 10.1002/cam4.1886. Epub 2018 Nov 19. PMID: 30453386; PMCID: PMC6308087.
- Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R., & Tsung, A. (2008). HMGB1: Endogenous danger signaling. In *Molecular Medicine*.  
<https://doi.org/10.2119/2008-00034.Klune>
- Lefrak, E. A., Pit'ha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer*.  
[https://doi.org/10.1002/1097-0142\(197308\)32:2<302::AID-CNCR2820320205>3.0.CO;2-2](https://doi.org/10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2)
- Li, W., Sama, A. E., & Wang, H. (2006). Role of HMGB1 in cardiovascular diseases. In *Current Opinion in Pharmacology*.  
<https://doi.org/10.1016/j.coph.2005.10.010>
- Liang, L., Fu, J., Wang, S., Cen, H., Zhang, L., Mandukhail, S. R., Du, L., Wu, Q., Zhang, P., & Yu, X. (2020). MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. *Acta Pharmaceutica Sinica B*.  
<https://doi.org/10.1016/j.apsb.2019.11.009>
- Luo, Y., Chihara, Y., Fujimoto, K., Sasahira, T., Kuwada, M., Fujiwara, R.,

- Fujii, K., Ohmori, H., & Kuniyasu, H. (2013). High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. *European Journal of Cancer*. <https://doi.org/10.1016/j.ejca.2012.09.016>
- Maral, R. J., & Jouanne, M. (1981). Toxicology of daunorubicin in animals and man. *Cancer Treatment Reports*, 65 Suppl 4, 9–18.
- McMurray, J., Komajda, M., Anker, S., & Gardner, R. (2015). Heart Failure: Epidemiology, Pathophysiology and Diagnosis. *Clinical Pharmacist*.
- Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019). Cancer treatment and survivorship statistics, 2019. *CA: A Cancer Journal for Clinicians*. <https://doi.org/10.3322/caac.21565>
- Mitry MA, Edwards JG. (2016). Doxorubicin induced heart failure: Phenotype and molecular mechanisms. *Int J Cardiol Heart Vasc*. 10:17-24. doi: 10.1016/j.ijcha.2015.11.004. PMID: 27213178; PMCID: PMC4871279.
- Mooney, C., Thomas, D. G. T., & Souhami, R. L. (1983). Adriamycin in the treatment of relapsed primary malignant brain tumours. In *European Journal of Cancer and Clinical Oncology*. [https://doi.org/10.1016/0277-5379\(83\)90074-3](https://doi.org/10.1016/0277-5379(83)90074-3)
- Movafagh S, Raj D, Sanaei-Ardekani M, Bhatia D, Vo K, Mahmoudieh M, Rahman R, Kim EH, Harralson AF. Hypoxia Inducible Factor 1: A Urinary Biomarker of Kidney Disease. *Clin Transl Sci*. 2017 May;10(3):201-207. doi: 10.1111/cts.12445. Epub 2017 Feb 9. PMID: 28181420; PMCID: PMC5421733.
- Naglova H, Bucova M. HMGB1 and its physiological and pathological roles. *Bratisl Lek Listy*. 2012;113(3):163-71. doi: 10.4149/bll\_2012\_039. PMID: 22428766.
- Nasution RA, Islam AA, Hatta M, Prihantono, Massi MN, Warsinggih, Kaelan C, Bahar B, Nasution KI, Wangi H, Faruk M. (2021). Effectiveness of CAPE in reducing vascular injury permeability. *Medicina Clínica Práctica*. 100229: 1-4. DOI: <https://doi.org/10.1016/j.mcpsp.2021.100229>
- Nobile-Orazio, E., Terenghi, F., Giannotta, C., Gallia, F., & Nozza, A. (2009). Serum vegf levels in poems syndrome and in immune-mediated neuropathies. *Neurology*. <https://doi.org/10.1212/01.wnl.0000344569.13496.ff>
- Oley MH, Oley MC, Noersasongko AD, Hatta M, Philips GG, Agustine, Faruk M, Kalangi JA, Rumampuk IMA, Tulong MT. (2021). Effects of hyperbaric oxygen therapy on vascular endothelial growth factor

protein and mRNA in crush injury patients: A randomized controlled trial study, *International Journal of Surgery Open*, 29;2021: 33-39. <https://doi.org/10.1016/j.ijso.2021.01.003>.

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., Decara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., ... Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging. *Journal of the American Society of Echocardiography*. <https://doi.org/10.1016/j.echo.2014.07.012>

Polonchuk, L., Chabria, M., Badi, L., Hoflack, J. C., Figtree, G., Davies, M. J., & Gentile, C. (2017). Cardiac spheroids as promising in vitro models to study the human heart microenvironment. *Scientific Reports*. <https://doi.org/10.1038/s41598-017-06385-8>

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., Davies, C. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. In *European Heart Journal*. <https://doi.org/10.1093/eurheartj/ehw128>

Purnamanita, Budu, Hatta M, Massi MN, Natzir R ,Ichsan AM, Sujuti H. (2020). The Effectiveness of Triamcinolone Injection on Risk of Postoperative Operations with the Conjunctiva Autograft Technique and Its Association with Change of VEGF mRNA Expression. *Biomed Pharmacol J* ;13(2); 543-549. DOI: <http://dx.doi.org/10.13005/bpj/1916>

Rauci, A., Di Maggio, S., Scavello, F., D'Ambrosio, A., Bianchi, M. E., & Capogrossi, M. C. (2019). The Janus face of HMGB1 in heart disease: a necessary update. In *Cellular and Molecular Life Sciences*. <https://doi.org/10.1007/s00018-018-2930-9>

Razavi-Azarkhiavi, K., Jaafari, M. R., Abnous, K., Razavi, B. M., Jafarian, A. H., Hassani, F. V., Shirani, K., & Karimi, G. (2017). The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations. *Pharmaceutical Research*. <https://doi.org/10.1007/s11095-017-2194-3>

Ridwan, E. (2013). Etika Pemanfaatan Hewan Percobaan dalam Penelitian Kesehatan. *J Indon Med Assoc*, 63, 112–118.

Rosamarlina R, Hatta M, Djaharuddin I, Patellongi I, Susanto A. D, Islam A.

- A, Massi M. N, Bukhari A, Santoso A, Tabri N. A, Murtiani F, Junita A. R, Saleh A. S, Dwiyantri R, Pakadang S. R. (2022). The Changes of HIF-1 $\alpha$  and ICAM-1 Expression after Miana (*Coleus Scutellarioides* [L]) Treatment in Balb/c Mice with Mycobacterium Tuberculosis Infection. *Biomed Pharmacol J.*15(1), 73-81. DOI: <https://dx.doi.org/10.13005/bpj/2344>
- Sirait RH, Hatta M, Ramli M, Islam AA, Arief SK. Systemic lidocaine inhibits high-mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury. *Saudi J Anaesth.* 2018 Jul-Sep;12(3):395-398. doi: 10.4103/sja.SJA\_685\_17. PMID: 30100837; PMCID: PMC6044174.
- Sirait RH, Hatta M, K.Arief S, Simanjuntak TP, Suprayogi B. 2018. Profile of HMGB1 mRNA Expression and TLR4 Protein in BALB/c Mice Model Sterile Injury after Systemic Lidocaine Administration. *Pharmacognosy Journal.* 10(3):586-589
- Shabariah R, Farsida, Hatta M, Patellongi I, Idris I, Santoso A, Islam AA, Natzir R, Wahyudin B, Warsinggih, Sanjoyo. (2022). Correlation between innate and adaptive immunity response in TB children post BCG vaccination. Is it effective or not?: Cross-sectional study. *Ann Med Surg (Lond).* 77:103586. doi: <https://doi.org/10.1016/j.amsu.2022.103586>
- Sanhueza, C., Wehinger, S., Castillo Bennett, J., Valenzuela, M., Owen, G. I., & Quest, A. F. G. (2015). The twisted survivin connection to angiogenesis. *Molecular Cancer.* <https://doi.org/10.1186/s12943-015-0467-1>
- Schlueter, C., Weber, H., Meyer, B., Rogalla, P., Röser, K., Hauke, S., & Bullerdiek, J. (2005). Angiogenetic signaling through hypoxia HMGB1: An angiogenetic switch molecule. *American Journal of Pathology.* [https://doi.org/10.1016/S0002-9440\(10\)62344-9](https://doi.org/10.1016/S0002-9440(10)62344-9)
- Scholz, C. C., & Taylor, C. T. (2013). Hydroxylase-dependent regulation of the NF-k $\beta$  pathway. In *Biological Chemistry.* <https://doi.org/10.1515/hsz-2012-0338>
- Schwartz, R. G., Jain, D., & Storzynsky, E. (2013). Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. In *Journal of Nuclear Cardiology.* <https://doi.org/10.1007/s12350-013-9707-1>
- Seidman, A., Hudis, C., Kathryn Pierri, M., Shak, S., Paton, V., Ashby, M., Murphy, M., Stewart, S. J., & Keefe, D. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. *Journal of Clinical Oncology.* <https://doi.org/10.1200/JCO.20.5.1215>
- Semenza, G. L., Rue, E. A., Iyer, N. V., Pang, M. G., & Kearns, W. G.



- (1996). Assignment of the hypoxia-inducible factor 1 $\alpha$  gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. *Genomics*. <https://doi.org/10.1006/geno.1996.0311>
- Semenza, Gregg L. (2003). Targeting HIF-1 for cancer therapy. In *Nature Reviews Cancer*. <https://doi.org/10.1038/nrc1187>
- Shibuya M. (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. *Genes Cancer*. 2(12):1097-105. doi: 10.1177/1947601911423031.
- Sishi, B. J. N. (2015). Autophagy Upregulation Reduces Doxorubicin-Induced Cardiotoxicity. In *Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging*. <https://doi.org/10.1016/B978-0-12-801033-4.00010-2>
- Speth, P. A. J., van Hoesel, Q. G. C. M., & Haanen, C. (1988). Clinical Pharmacokinetics of Doxorubicin. In *Clinical Pharmacokinetics*. <https://doi.org/10.2165/00003088-198815010-00002>
- Sumita Yoshikawa W, Nakamura K, Miura D, Shimizu J, Hashimoto K, Kataoka N, Toyota H, Okuyama H, Miyoshi T, Morita H, Fukushima Kusano K, Matsuo T, Takaki M, Kajiya F, Yagi N, Ohe T, Ito H. (2013). Increased passive stiffness of cardiomyocytes in the transverse direction and residual actin and myosin cross-bridge formation in hypertrophied rat hearts induced by chronic  $\beta$ -adrenergic stimulation. *Circ J*. 77(3):741-8. doi: 10.1253/circj.cj-12-0779.
- Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer*. <https://doi.org/10.1002/cncr.11407>
- Syukri A, Budu, Hatta M, Amir M, Rohman MS, Mappangara I, Kaelan C, Wahyuni S, Bukhari A, Junita AR, Primaguna MR, Dwiyantri R, Febrianti A. (2022). Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1- $\alpha$  and VEGF pathway in progressive of cardiovascular damage. *Ann Med Surg (Lond)*. 21;76:103501. <https://doi.org/10.1016/j.amsu.2022.103501>
- Syukri A, Budu, Hatta M, Amir M, Rohman SM, Mappangara I, Kaelan C, Wahyuni S, Bukhari A, Junita AR, Primaguna MR, Dwiyantri R, Febrianti A, Azhar A, Kesumasari D, Andini NS. (2023). Effect of Doxorubicin (DOX) induction on mRNA expression of High-mobility group box 1 (HMGB1) and protein levels in Balb/c mice: A cohort experimental study. *The Pan African Medical Journal*. No.40364. Reviewed, May 16, 2023.
- Taufik SA, Dirja BT, Utomo DN, Usman MA, Sakti M, Saleh MR, Hatta M, Budu. (2023). Double membrane platelet-rich fibrin (PRF) - Synovium

succeeds in regenerating cartilage defect at the knee: An experimental study on rabbit. *Heliyon*. 9(2):e13139. doi: <https://doi.org/10.1016/j.heliyon.2023.e13139>

Tommy T, Islam AA, Hatta M, Bukhari A, Nasrullah, Adhimarta W, Aminuddin, Zainuddin AA. (2021). Effect of folic acid on serum homocysteine, TNF $\alpha$ , IL-10, and HMGB1 gene expression in head injury model. *Ann Med Surg (Lond)*.65:102273. doi: 10.1016/j.amsu.2021.102273. PMID: 33996045; PMCID: PMC8100092.

Tommy T, Islam AA, Hatta M, Bukhari A. (2020). Immunomodulatory properties of high mobility group box 1 and its potential role in brain injury: Review article. *Ann Med Surg (Lond)*. 59:106-109. doi: 10.1016/j.amsu.2020.09.025. PMID: 32994992; PMCID: PMC7511818.

Triantafyllou, A., Mylonis, I., Simos, G., Bonanou, S., & Tsakalof, A. (2008). Flavonoids induce HIF-1 $\alpha$  but impair its nuclear accumulation and activity. *Free Radical Biology and Medicine*. <https://doi.org/10.1016/j.freeradbiomed.2007.10.050>

Vyas, D., Laput, G., & Vyas, A. K. (2014). Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. In *OncoTargets and Therapy*. <https://doi.org/10.2147/OTT.S60114>

Wahyudi, Islam AA, Hatta M, Adhimarta W, Faris M, Mustamir N, Bukhari A, Prihantono, Kaelan C, Hendarto J, Imran NH, Rosyidi RM. The role of MLC901 in reducing VEGF as a vascular permeability marker in rats with spinal cord injury. *Ann Med Surg (Lond)*. 2022 Feb 5;75:103344. doi: 10.1016/j.amsu.2022.103344. PMID: 35386787; PMCID: PMC8977894.

Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A., & Tracey, K. J. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. *Science*. <https://doi.org/10.1126/science.285.5425.248>

Wardani IS, Hatta M, Mubin RH, Bukhari A, Mulyanto, Massi MN, Djaharuddin I, Bahar B, Aminuddin, Wahyuni S. (2021). Serum vitamin D receptor and High Mobility Group Box-1 (HMGB1) levels in HIV-infected patients with different immunodeficiency status: A cross-sectional study. *Ann Med Surg (Lond)*. 63:102174. doi: 10.1016/j.amsu.2021.02.020. PMID: 33664952; PMCID: PMC7900012.

Wenger, R. H. (2002). Cellular adaptation to hypoxia: O<sub>2</sub> -sensing protein

hydroxylases, hypoxia-inducible transcription factors, and O<sub>2</sub>-regulated gene expression. *The FASEB Journal*. <https://doi.org/10.1096/fj.01-0944rev>

- Wijaya I, Taslim NA, Natzir R, Aman AM, Hatta M, Patellongi I, Suhudi B, Islam AA, Massi MN, Ichsan AM. (2020). Molecular and Immunological Mechanisms of *Channa striata* in Diabetic Wound Healing. *International Journal of Pharmaceutical Research* 12 | Supplementary Issue 2: 279-289. DOI: <https://doi.org/10.31838/ijpr/2020.SP2.046>.
- Yanto T. A, Hatta M, Bukhari A, Natzir R. Molecular and Immunological Mechanisms of Miana Leaf (*Coleus Scutellariodes* [L] Benth) in Infectious Diseases. *Biomed Pharmacol J* 2020;13(4): 1607-1618. <https://dx.doi.org/10.13005/bpj/2036>
- Yao, Y., Xu, X., Zhang, G., Zhang, Y., Qian, W., & Rui, T. (2012). Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. *Basic Research in Cardiology*. <https://doi.org/10.1007/s00395-012-0267-3>
- Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., Achenbach, S., Agewall, S., Badimon, L., ... Szmit, S. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. In *European Heart Journal*. <https://doi.org/10.1093/eurheartj/ehw211>
- Zhao, L., & Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. *Scientific Reports*. <https://doi.org/10.1038/srep44735>
- Zhu, R., Wang, Z., Liang, P., He, X., Zhuang, X., Huang, R., Wang, M., Wang, Q., Qian, Y., & Wang, S. (2017). Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO<sub>2</sub>@LDH for anti-neuroblastoma therapy. *Acta Biomaterialia*. <https://doi.org/10.1016/j.actbio.2017.09.009>
- Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale J Biol Med*. 2007 Jun;80(2):51-60. PMID: 18160990; PMCID: PMC2140184.





Contents lists available at ScienceDirect

Annals of Medicine and Surgery

journal homepage: [www.elsevier.com/locate/amsu](http://www.elsevier.com/locate/amsu)

Systematic Review / Meta-analysis

## Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1- $\alpha$ and VEGF pathway in progressive of cardiovascular damage

Ahmad Syukri <sup>a,c</sup>, Budu <sup>b</sup>, Mochammad Hatta <sup>c,\*</sup>, Muzakkir Amir <sup>d</sup>, Mohammad Saifur Rohman <sup>e</sup>, Idar Mappangara <sup>d</sup>, Cahyono Kaelan <sup>f</sup>, Siti Wahyuni <sup>g</sup>, Agussalim Bukhari <sup>h</sup>, Ade Rifka Junita <sup>a,c</sup>, Muhammad Reza Primaguna <sup>i</sup>, Ressay Dwiyantri <sup>j,k</sup>, Andini Febrianti <sup>k</sup>

<sup>a</sup> Post Graduate School, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>b</sup> Department of Ophthalmology, Faculty of Medicine Hasanuddin University, Makassar, Indonesia

<sup>c</sup> Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>d</sup> Department Cardiology and Vascular Medicine, Faculty of Medicine Hasanuddin University, Makassar, Indonesia

<sup>e</sup> Department of Cardiology and Vascular Medicine, Faculty of Medicine, Saiful Anwar General Hospital, Brawijaya University, Malang, East Java, Indonesia

<sup>f</sup> Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>g</sup> Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>h</sup> Department of Nutrition, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>i</sup> Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>j</sup> Department of Medical Microbiology, Faculty of Medicine, Tadulako University, Palu, Indonesia

<sup>k</sup> Department of Forensic and Medicolegal, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Your ORCID ID is

ORCID ID

<https://orcid.org/0000-0002-8456-4203> [Unlink this ORCID ID]

Update my details

My active manuscripts (Click on title to expand contents)

Submit a new manuscript



Published



In peer-review



Accepted. In Quality Control

- 1 Effect of Doxorubicin (DOX) induction on mRNA expression of High-mobility group box 1 (HMGB1) and protein levels in Balb/c mice: A cohort experimental study [40354 - Submitted on 09 May 23]

History

[Journal: PAMJ]



### The following actions were taken on your submission.

2023-05-09 - Manuscript submitted (By Mochammad Hatta, MD, PhD, Prof(022797))

Initial Manuscript submission to Pan African Medical Journal



Published



In peer-review



Accepted. In Quality Control

- 1 Effect of Doxorubicin (DOX) induction on mRNA expression of High-mobility group box 1 (HMGB1) and protein levels in Balb/c mice: A cohort experimental study [40364 - Submitted on 10 May 23]

History

[Journal: PAMJ]



Re-submit

### The following actions were taken on your submission.

2023-05-10 - Manuscript submitted (By Mochammad Hatta, MD, PhD, Prof(022797))

Initial Manuscript submission to Pan African Medical Journal

2023-05-12 - Revised version of manuscript submitted (By Mochammad Hatta, MD, PhD, Prof-0000-0002-8456-4203(022797))

Dear Editor, We have changed according to the comments of the Editor and added the STROBE checklist as an Annex to the manuscript's main text. Thank you for your kind cooperation. Best wishes, Prof. Mochammad Hatta, MD, PhD

2023-05-16 - Revised version of manuscript submitted (By Mochammad Hatta, MD, PhD, Prof(022797))

17 May 2023 Dear Editors, Herewith submit the second revision of the manuscript according to comments and corrections. We have changed the text citation to a sequence bracket [X] Also changed all images in Figure 1, 2, and 3 with high resolution and not corrupted during the submission. Thank you for your comments, corrections, and cooperation. best wishes, Prof. Mochammad Hatta, MD, PhD Correspondence authors

